152 related articles for article (PubMed ID: 30694563)
1. Screen-detected and interval colorectal cancers in England: Associations with lifestyle and other factors in women in a large UK prospective cohort.
Blanks R; Burón Pust A; Alison R; He E; Barnes I; Patnick J; Reeves GK; Floud S; Beral V; Green J
Int J Cancer; 2019 Aug; 145(3):728-734. PubMed ID: 30694563
[TBL] [Abstract][Full Text] [Related]
2. Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women.
Blanks RG; Benson VS; Alison R; Brown A; Reeves GK; Beral V; Patnick J; Green J
Br J Cancer; 2015 Apr; 112(9):1562-7. PubMed ID: 25742470
[TBL] [Abstract][Full Text] [Related]
3. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
[TBL] [Abstract][Full Text] [Related]
4. Association of ten gastrointestinal and other medical conditions with positivity to faecal occult blood testing in routine screening: a large prospective study of women in England.
He E; Alison R; Blanks R; Pirie K; Reeves G; Ward RL; Steele R; Patnick J; Canfell K; Beral V; Green J
Int J Epidemiol; 2019 Apr; 48(2):549-558. PubMed ID: 30668711
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
6. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
7. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests.
Logan RF; Patnick J; Nickerson C; Coleman L; Rutter MD; von Wagner C;
Gut; 2012 Oct; 61(10):1439-46. PubMed ID: 22156981
[TBL] [Abstract][Full Text] [Related]
9. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
[TBL] [Abstract][Full Text] [Related]
10. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
[TBL] [Abstract][Full Text] [Related]
11. Interval Colorectal Cancers following Guaiac Fecal Occult Blood Testing in the Ontario ColonCancerCheck Program.
Paszat L; Sutradhar R; Tinmouth J; Baxter N; Rabeneck L
Can J Gastroenterol Hepatol; 2016; 2016():4768728. PubMed ID: 27446842
[TBL] [Abstract][Full Text] [Related]
12. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
[TBL] [Abstract][Full Text] [Related]
13. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
Guo F; De Brabander I; Francart J; Candeur M; Polus M; Van Eycken L; Brenner H
Br J Cancer; 2020 Mar; 122(7):1109-1117. PubMed ID: 32066910
[TBL] [Abstract][Full Text] [Related]
14. Text Reminders in Colorectal Cancer Screening (TRICCS): Protocol for a randomised controlled trial.
Hirst Y; Kerrison R; Kobayashi LC; Counsell N; Djedovic N; Ruwende J; Stewart M; von Wagner C
BMC Public Health; 2016 Jan; 16():74. PubMed ID: 26809344
[TBL] [Abstract][Full Text] [Related]
15. The contribution of a negative colorectal screening test result to symptom appraisal and help-seeking behaviour among patients subsequently diagnosed with an interval colorectal cancer.
Barnett KN; Weller D; Smith S; Steele RJ; Vedsted P; Orbell S; Moss SM; Melia JW; Patnick J; Campbell C
Health Expect; 2018 Aug; 21(4):764-773. PubMed ID: 29457677
[TBL] [Abstract][Full Text] [Related]
16. A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme.
Morris EJ; Whitehouse LE; Farrell T; Nickerson C; Thomas JD; Quirke P; Rutter MD; Rees C; Finan PJ; Wilkinson JR; Patnick J
Br J Cancer; 2012 Aug; 107(5):757-64. PubMed ID: 22850549
[TBL] [Abstract][Full Text] [Related]
17. Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme.
Kearns B; Whyte S; Chilcott J; Patnick J
Br J Cancer; 2014 Oct; 111(9):1734-41. PubMed ID: 25180767
[TBL] [Abstract][Full Text] [Related]
18. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
19. Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy.
Young C; Wood HM; Fuentes Balaguer A; Bottomley D; Gallop N; Wilkinson L; Benton SC; Brealey M; John C; Burtonwood C; Thompson KN; Yan Y; Barrett JH; Morris EJA; Huttenhower C; Quirke P
Clin Cancer Res; 2021 Apr; 27(8):2246-2254. PubMed ID: 33658300
[TBL] [Abstract][Full Text] [Related]
20. Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm.
Geraghty J; Butler P; Seaman H; Snowball J; Sarkar S; Blanks R; Halloran S; Bodger K; Rees CJ
Br J Cancer; 2014 Nov; 111(11):2156-62. PubMed ID: 25225905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
